{
  "payload": {
    "molecule": "Nintedanib",
    "recommendation": "No-Go",
    "market_score": 48,
    "innovation_story": "Nintedanib continues to underperform in systemic sclerosis lung cohorts, with dose-limiting liver toxicity and expiring IP leaving little upside for repurposing beyond its approved IPF label.",
    "workers": {
      "clinical": {
        "summary": "Phase 2 SSc-ILD add-on failed to hit FVC endpoints and showed elevated discontinuations from hepatic AEs.",
        "confidence": 0.42,
        "confidence_band": "low",
        "evidence": [
          {
            "type": "Trial",
            "text": "SENSCIS sub-study reported -95 mL vs placebo with 18% discontinuations due to liver enzyme spikes.",
            "url": "https://clinicaltrials.gov/study/NCT02597933",
            "confidence": 0.4
          }
        ]
      },
      "patent": {
        "summary": "Core composition patents lapse by 2026 and combination filings are already contested across EU courts.",
        "confidence": 0.46,
        "confidence_band": "low",
        "evidence": [
          {
            "type": "Patent",
            "text": "EP2245213 opposition decision limits exclusivity to specific crystalline forms, exposing generics.",
            "url": "https://example.org/patent/ep2245213",
            "confidence": 0.42
          }
        ]
      }
    },
    "quality": {
      "status": "investigate",
      "alerts": {
        "clinical": ["Low precision proxy (0.40 < 0.50)"]
      }
    }
  }
}
